期刊
SCHIZOPHRENIA RESEARCH
卷 235, 期 -, 页码 44-51出版社
ELSEVIER
DOI: 10.1016/j.schres.2021.07.008
关键词
Cognition; Noninvasive brain stimulation; Transcranial direct current stimulation (tDCS); Schizophrenia; Negative symptoms; Cognitive factors
类别
资金
- Stanley Medical Research Institute [12T-011]
- Sao Paulo Research State Foundation [17/50223-7]
- Beneficent Association Alzira Denise Hertzog da Silva
- National Institute of Science and Technology program National Institute of Biomarkers in Psychiatry (INBioN) [14/50873-3]
- German Center for Brain Stimulation research consortium - German Federal Ministry of Education and Research [01EE1403E]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [17/50223-7] Funding Source: FAPESP
The study found that transcranial direct current stimulation (tDCS) did not effectively improve cognitive function in patients with schizophrenia, and sham-tDCS performed better in some tests. This suggests that modifications to the tDCS treatment protocol may be needed to enhance its effects on cognition.
Cognitive deficits and negative symptoms in schizophrenia are associated with poor functional outcomes and limited in terms of treatment. The Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) trial has shown efficacy of transcranial direct current stimulation (tDCS) for improving negative symptoms. In this secondary analysis, we investigate its effects on cognitive performance. In STARTS, a double-blinded, sham controlled, randomized clinical trial, patients were treated with twice-daily, 20-min, 2-mA fronto-temporal tDCS over 5 days or sham-tDCS. In 90 patients, we evaluated the cognitive performance up to 12 weeks post-treatment. We found that active-tDCS showed no beneficial effects over sham-tDCS in any of the tests. Based on a 5-factor cognitive model, improvements of executive functions and delayed memory were observed in favor of shamtDCS. Overall, the applied active-tDCS protocol, primarily designed to improve negative symptoms, did not promote cognitive improvement. We discuss possible protocol modification potentially required to increase tDCS effects on cognition. ClinicalTrials.gov identifier: NCT02535676
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据